Vaccine enhancement through antigen targeting

描述(申请人提供)：目前非常需要新的和更有效的疫苗。以重组蛋白、纯化亚基或多肽为基础的疫苗往往会引起免疫反应不良，导致疫苗接种失败。我们的解决方案是开发更有效的疫苗，更直接地将抗原靶向抗原提呈细胞。在这项第一阶段提案中，我们正在进行可行性研究，以测试FcRL作为疫苗组成部分的使用情况。当作为疫苗的一部分使用时，FcRLS有效地靶向与抗原提呈细胞结合的抗原。我们的第一阶段目标是1)确定使用弱重组抗原免疫所需的最佳佐剂系统和最小剂量，2)建立该系统使用多肽抗原的有效性，3)研究FcRLS与其他当前疫苗配方结合使用作为增强的适用性，以及4)表征FcRL诱导的抗体反应。如果第一阶段的数据表明可以使用FcRLS设计出更好的疫苗，那么在第二阶段，我们将设计一种原型疫苗(S)，用于递送多肽抗原或重组亚单位。商业潜力：发达国家的几乎所有个人以及几乎所有家养动物目前都接种了疫苗。如果新的适应症可以通过更好的疫苗来解决，那么对这些产品的需求将是巨大的。同样巨大的是对人类和动物健康和福祉的潜在好处。

DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vaccination. Our solution is to develop more effective vaccines that target antigens to antigen presenting cells more directly. In this Phase I proposal we are performing feasibility studies to test the use of FcRLs as a component of vaccines. When used as part of a vaccine, FcRLs effectively target attached antigens to antigen presenting cells. Our Phase I goals are 1) To determine a best adjuvant system and minimum dose necessary for immunization using a weak recombinant antigen, 2) establish efficacy of this system for the use of peptides antigens, 3) to investigate the applicability of using FcRLs as a boost in combination with other current vaccine formulations and 4) characterize FcRL-induced antibody responses. Should Phase I data indicate that better vaccines can be designed using FcRLs, in Phase II we will design a prototype vaccine(s) for delivery of peptide antigens or recombinant subunits. Commercial Potential: Essentially all individuals in the developed world as well as nearly all domesticated animals are currently vaccinated. If new indications could be addressed by better vaccines then the demand for these products would be vast. Equally vast would be the potential benefit to human and animal health and well-being.